Medical School · Year 2 · Hematology Oncology · includes a quiz and discussion video

Lecture 11: Plasma Cell Disorders

Unit 2.9: Hematology/Oncology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the spectrum of plasma cell disorders
2. Explain the pathophysiology and diagnosis of multiple myeloma
3. Describe the clinical manifestations of multiple myeloma
4. Explain the treatment of multiple myeloma
5. Describe MGUS and smoldering myeloma
6. Explain AL amyloidosis and Waldenström macroglobulinemia

Lecture Outline

I. Plasma Cell Disorders Overview

Plasma cell disorders represent a spectrum of conditions unified by the clonal proliferation of plasma cells that produce a monoclonal immunoglobulin, commonly referred to as an M-protein or paraprotein, with clinical significance ranging from the benign monoclonal gammopathy of undetermined significance to the malignant and life-threatening multiple myeloma. At the most indolent end of this spectrum, MGUS is defined by the presence of a monoclonal protein without evidence of organ damage, while smoldering myeloma demonstrates higher levels of M-protein or bone marrow plasma cells but still lacks end-organ damage. Multiple myeloma represents the fully malignant form with both high M-protein levels and characteristic organ injury. Beyond myeloma, the spectrum extends to plasma cell leukemia with circulating malignant plasma cells in the blood, AL amyloidosis where misfolded light chains deposit in tissues causing organ dysfunction, and Waldenstrom macroglobulinemia where an IgM-producing lymphoplasmacytic neoplasm causes hyperviscosity syndrome.

The monoclonal protein produced by the clonal plasma cell population serves as both a diagnostic marker and a mediator of disease pathology. M-protein is defined as a single immunoglobulin species produced by one clone, detectable as a sharp spike on serum protein electrophoresis (SPEP) in the gamma globulin region. Quantification of the M-protein is performed by densitometry of the SPEP spike, providing a measure of disease burden that can be tracked over time. Immunofixation electrophoresis identifies the specific type of M-protein by determining the heavy chain class and light chain type. The serum free light chain assay measures unbound kappa and lambda light chains and is particularly important for detecting disease in patients with light chain only myeloma or AL amyloidosis where intact immunoglobulin may not produce a detectable SPEP spike.

The types of monoclonal proteins produced in myeloma reflect the immunoglobulin class of the malignant clone, with important implications for disease behavior and complications. IgG is the most common M-protein type, accounting for approximately 50 percent of myeloma cases, followed by IgA at approximately 20 percent. Light chain only myeloma, in which the malignant clone produces free light chains without intact immunoglobulin, represents 15 to 20 percent of cases and carries a higher risk of renal complications due to the nephrotoxic properties of free light chains. IgD myeloma is rare at approximately 2 percent of cases, biclonal gammopathy with two distinct M-proteins is uncommon, and non-secretory myeloma in which the malignant plasma cells do not produce detectable M-protein occurs in approximately 3 percent of cases and requires alternative methods for monitoring disease.

The pathophysiology of plasma cell disorders centers on the consequences of clonal plasma cell expansion within the bone marrow and the effects of the monoclonal protein and associated cytokines on distant organs. Clonal plasma cells progressively infiltrate the bone marrow, displacing normal hematopoietic elements and causing cytopenias. The M-protein itself can cause hyperviscosity syndrome, particularly with IgA or high levels of any immunoglobulin, and free light chains are directly toxic to the renal tubules. Malignant plasma cells secrete interleukin-6 and other cytokines that stimulate osteoclast activity and suppress osteoblast function, while the imbalance between RANKL (receptor activator of nuclear factor kappa-B ligand) and its decoy receptor osteoprotegerin (OPG) drives the characteristic osteolytic bone destruction that distinguishes myeloma from most metastatic bone disease.

<image>Panel A: Disease spectrum from MGUS with 1% per year progression risk through smoldering myeloma with 10% per year risk to active myeloma. Panel B: Serum protein electrophoresis showing characteristic M-spike in gamma region with densitometry quantification. Panel C: Immunofixation electrophoresis identifying M-protein type as IgG kappa or other immunoglobulin class. Panel D: Pathophysiology diagram showing clonal plasma cell expansion, cytokine release, RANKL/OPG imbalance, and resulting bone disease.</image>

II. Multiple Myeloma - Diagnosis

The diagnosis of multiple myeloma according to the 2014 International Myeloma Working Group criteria requires the presence of 10 percent or more clonal bone marrow plasma cells plus evidence of end-organ damage as defined by the CRAB criteria or the presence of one or more myeloma-defining events. This diagnostic framework ensures that treatment is initiated only when the disease has caused or is imminently threatening to cause significant organ injury, while patients without such evidence are classified as having smoldering myeloma and typically observed. The incorporation of myeloma-defining events into the diagnostic criteria in 2014 represented an important advance, allowing treatment to begin before overt organ damage occurs in patients at very high risk of imminent progression. The distinction between active myeloma requiring treatment and its precursor conditions requiring only monitoring is fundamental to the management of plasma cell disorders.

The CRAB criteria define the four cardinal manifestations of end-organ damage in multiple myeloma and serve as the traditional indications for initiating treatment. Calcium elevation, defined as serum calcium greater than 11 mg/dL or more than 1 mg/dL above the upper limit of normal, results from osteoclast-mediated bone resorption and can cause confusion, constipation, polyuria, and cardiac arrhythmias. Renal insufficiency, defined as creatinine greater than 2 mg/dL or creatinine clearance less than 40 mL per minute, may result from multiple mechanisms including light chain cast nephropathy, hypercalcemia, and amyloid deposition. Anemia, defined as hemoglobin less than 10 g/dL or more than 2 g below the lower limit of normal, reflects bone marrow infiltration by plasma cells and cytokine-mediated suppression of erythropoiesis. Bone lesions, detected as lytic lesions on skeletal imaging, represent the most common presenting feature and cause substantial morbidity through pain, pathologic fractures, and hypercalcemia.

The myeloma-defining events identify patients at ultra-high risk of progression to symptomatic disease who benefit from early treatment even in the absence of CRAB criteria. Bone marrow plasma cells of 60 percent or more indicate such extensive marrow infiltration that organ damage is virtually inevitable without intervention. A serum free light chain ratio of 100 or more, with the involved light chain being the numerator, identifies patients with markedly abnormal light chain production at high risk of rapid progression. The presence of more than one focal lesion of 5 mm or greater on MRI indicates significant skeletal involvement that may not yet manifest as lytic lesions on conventional radiography. These biomarkers of impending malignancy allow earlier treatment initiation and represent a shift toward risk-based rather than damage-based treatment criteria.

The laboratory workup for suspected multiple myeloma is comprehensive and serves both diagnostic and prognostic purposes. A complete blood count evaluates for anemia that may reflect marrow infiltration, while creatinine and calcium measurements assess for the R and C of CRAB criteria. Serum protein electrophoresis and urine protein electrophoresis detect and quantify the monoclonal protein, while immunofixation determines the specific M-protein type. The serum free light chain assay quantifies kappa and lambda light chains and calculates the ratio, essential for light chain myeloma and for identifying myeloma-defining events. Lactate dehydrogenase and beta-2-microglobulin are critical prognostic markers used in staging, while bone marrow biopsy provides the plasma cell percentage, tissue for cytogenetic analysis by FISH, and confirmation of clonality.

<image>Panel A: CRAB criteria mnemonic showing Calcium elevation, Renal insufficiency, Anemia, and Bone lesions with specific thresholds. Panel B: Bone marrow aspirate demonstrating greater than 10% clonal plasma cells with eccentric nuclei and perinuclear clearing. Panel C: SPEP with prominent M-spike and corresponding immunofixation confirming monoclonal protein type. Panel D: Myeloma-defining events including 60% or greater bone marrow plasma cells, free light chain ratio of 100 or greater, and multiple MRI focal lesions.</image>

III. Multiple Myeloma - Clinical Features

Bone disease is the most characteristic and debilitating clinical manifestation of multiple myeloma, resulting from the imbalance between osteoclast-mediated bone resorption and suppressed osteoblast activity driven by cytokines and the RANKL/OPG axis. The classic radiographic finding consists of "punched out" lytic lesions that appear as sharply defined holes without a surrounding sclerotic rim, most commonly found in the skull, spine, ribs, and pelvis where active red marrow is present. Bone pain is the most common presenting symptom of multiple myeloma and may be the complaint that initiates the diagnostic evaluation. Pathologic fractures, particularly vertebral compression fractures and fractures of the long bones, cause significant morbidity and may lead to spinal cord compression requiring urgent intervention. Hypercalcemia from excessive bone resorption causes the characteristic symptoms of "stones, bones, groans, and moans" and requires urgent management. A critically important diagnostic pearl is that conventional bone scans (technetium-99m) are often negative in myeloma because the osteoblastic activity that takes up the radiotracer is suppressed, unlike metastatic carcinoma where both osteolytic and osteoblastic activity are present, making whole-body low-dose CT or PET-CT the preferred imaging modalities.

Renal disease in multiple myeloma results from multiple pathogenic mechanisms that may act independently or in combination to produce acute or chronic kidney injury. Cast nephropathy, also known as myeloma kidney, is the most common renal complication and occurs when monoclonal free light chains combine with Tamm-Horsfall protein in the distal tubules to form obstructing intratubular casts that cause tubular injury and interstitial inflammation. Hypercalcemia causes direct renal tubular injury through vasoconstriction, nephrogenic diabetes insipidus, and calcium deposition. AL amyloidosis from light chain deposition causes nephrotic syndrome through glomerular injury, while non-amyloid light chain deposition disease produces a pattern of nodular glomerulosclerosis. The use of iodinated contrast media carries increased risk in myeloma patients due to the potential for precipitation of light chains in the tubules, though this risk may be lower than historically believed. The presentation may be acute kidney injury, chronic kidney disease, or nephrotic syndrome depending on the dominant mechanism.

Hematologic abnormalities in multiple myeloma extend beyond anemia and reflect the multifaceted impact of the disease on blood cell production and function. Anemia is present in the majority of patients and results from both marrow infiltration by plasma cells displacing normal erythroid precursors and cytokine-mediated suppression of erythropoiesis. Rouleaux formation, the characteristic stacking of red blood cells resembling coins, is caused by the elevated M-protein concentration increasing erythrocyte surface charge interactions and is a classic peripheral smear finding that should prompt evaluation for a plasma cell disorder. The M-protein can interfere with coagulation factors leading to coagulopathy, and the phenomenon of a spuriously elevated or decreased laboratory value due to M-protein interference should be recognized. Thrombocytopenia is typically a late finding occurring with extensive marrow infiltration.

Additional clinical features of multiple myeloma reflect the systemic effects of immune dysfunction, monoclonal protein deposition, and tumor mass. Recurrent infections represent a major source of morbidity and mortality, resulting from hypogammaglobulinemia caused by suppression of normal immunoglobulin production even as the malignant clone produces excessive amounts of a single non-functional monoclonal protein. Peripheral neuropathy may result from AL amyloid deposition in nerves or from cryoglobulinemia associated with the M-protein. Hyperviscosity syndrome, though more characteristic of Waldenstrom macroglobulinemia, can occur in myeloma particularly with IgA M-proteins which tend to polymerize, or with very high M-protein levels of any type. Plasmacytomas, which are localized tumor masses of malignant plasma cells, may occur either within bone as intramedullary lesions or in soft tissues as extramedullary plasmacytomas.

<image>Panel A: Skull X-ray demonstrating multiple punched-out lytic lesions without sclerotic rim characteristic of myeloma bone disease. Panel B: Peripheral blood smear showing rouleaux formation with red blood cells stacked like coins due to M-protein. Panel C: Kidney biopsy with cast nephropathy showing eoite casts composed of light chains and Tamm-Horsfall protein in tubules. Panel D: Clinical manifestations diagram showing bone pain sites, pathologic fracture risk, and hypercalcemia symptoms.</image>

IV. Multiple Myeloma - Staging and Prognosis

The Revised International Staging System (R-ISS) integrates serum biomarkers and cytogenetic risk to stratify multiple myeloma patients into three prognostic groups that predict survival and guide treatment intensity. Stage I requires beta-2-microglobulin less than 3.5 mg/L, serum albumin 3.5 g/dL or greater, standard-risk cytogenetics, and normal LDH, and carries the most favorable prognosis with a median survival of 82 months. Stage II encompasses patients who do not meet criteria for either stage I or stage III and demonstrates intermediate prognosis with a median survival of 62 months. Stage III is defined by beta-2-microglobulin of 5.5 mg/L or greater combined with either high-risk cytogenetics or elevated LDH, and carries the worst prognosis with a median survival of 40 months. This staging system provides a practical framework for risk stratification using readily available laboratory tests and genetic information.

Cytogenetic risk assessment by fluorescence in situ hybridization is a cornerstone of myeloma prognostication and increasingly influences treatment selection. Standard-risk abnormalities include trisomies (hyperdiploidy) and the t(11;14) translocation, which are associated with more favorable outcomes with standard therapy. High-risk abnormalities include deletion of 17p, which results in loss of the TP53 tumor suppressor and confers particularly adverse prognosis, t(4;14) which creates the FGFR3-MMSET fusion, t(14;16) which activates the MAF oncogene, and gain of chromosome 1q which has emerged as an important adverse marker. The presence of multiple high-risk cytogenetic abnormalities compounds the adverse prognosis, and patients with high-risk genetics are increasingly considered for more intensive treatment strategies including tandem transplantation and aggressive maintenance regimens.

Multiple prognostic factors beyond the R-ISS staging contribute to outcome prediction in multiple myeloma and inform clinical decision-making. Beta-2-microglobulin reflects tumor burden and renal function, serving as the single most important prognostic biomarker. Serum albumin provides a measure of overall health status and nutritional state. Elevated LDH indicates aggressive disease biology with high cell turnover. Cytogenetic abnormalities determined by FISH define the intrinsic biology of the malignant clone and predict response to specific therapies. Renal function at diagnosis independently affects outcomes, as patients presenting with significant renal impairment have worse overall survival. Patient age and performance status determine tolerance to therapy and influence treatment intensity decisions, particularly regarding transplant eligibility.

Response assessment in multiple myeloma follows standardized criteria based on the depth of M-protein reduction and increasingly incorporates assessment of minimal residual disease. Complete response is defined as negative immunofixation of serum and urine, indicating that the M-protein has been reduced below the detection threshold of this sensitive assay. Very good partial response represents a 90 percent or greater reduction in serum M-protein, indicating substantial disease control. Partial response requires a 50 percent or greater reduction in M-protein. The most sensitive response category, minimal residual disease negativity, indicates that no detectable disease remains when assessed by either multicolor flow cytometry or next-generation sequencing at a sensitivity of one malignant cell per 100,000 to 1,000,000 normal cells. Achieving deeper responses, particularly MRD negativity, has been associated with improved progression-free and overall survival, making depth of response an increasingly important treatment goal.

<image>Panel A: Revised ISS staging system with beta-2-microglobulin, albumin, LDH, and cytogenetics determining stages I through III with median survival. Panel B: Cytogenetic risk stratification showing standard risk trisomies and t(11;14) versus high risk del(17p), t(4;14), t(14;16), and gain 1q. Panel C: Response criteria definitions from partial response through complete response to MRD-negative status. Panel D: Prognostic factor impact on survival including renal function, age, performance status, and genetic features.</image>

V. Multiple Myeloma - Treatment

The treatment of multiple myeloma follows a structured approach built around triplet drug therapy as the backbone, with the goal of achieving deep and durable disease control through sequential phases of induction, transplantation when eligible, and maintenance therapy. Triplet therapy combining three active agents from different drug classes provides the optimal balance of efficacy and tolerability for induction. Transplant-eligible patients proceed to stem cell collection followed by autologous stem cell transplantation after achieving initial disease control. Consolidation and maintenance therapy following transplantation or induction in non-transplant patients aims to prolong remission and prevent relapse. Therapy is generally continuous, administered until disease progression or intolerance, reflecting the current incurability of myeloma and the need for ongoing disease suppression.

The major drug classes used in myeloma treatment each exploit distinct vulnerabilities of malignant plasma cells. Proteasome inhibitors including bortezomib, carfilzomib, and ixazomib block the proteasome responsible for degrading misfolded proteins, causing toxic accumulation of proteins within the endoplasmic reticulum-stressed plasma cell. Immunomodulatory drugs (IMiDs) including lenalidomide, pomalidomide, and thalidomide exert multiple effects including direct anti-myeloma activity, immunomodulation that enhances anti-tumor immune responses, and anti-angiogenic properties. Anti-CD38 monoclonal antibodies including daratumumab and isatuximab target the CD38 surface protein highly expressed on myeloma cells and have become essential components of modern myeloma therapy. Corticosteroids, particularly dexamethasone, provide direct lympholytic activity and synergize with other agents. Alkylating agents including melphalan and cyclophosphamide remain important, with high-dose melphalan serving as the conditioning regimen for autologous transplantation.

Standard treatment regimens are selected based on transplant eligibility, which is determined primarily by age and comorbidities. For transplant-eligible patients, VRd (bortezomib, lenalidomide, and dexamethasone) has been the standard induction regimen, with DRd (daratumumab, lenalidomide, dexamethasone) emerging as an alternative incorporating anti-CD38 therapy upfront. For transplant-ineligible patients, DRd or VRd is administered as continuous therapy. Following 4 to 6 cycles of induction, transplant-eligible patients undergo stem cell collection and high-dose melphalan conditioning followed by autologous stem cell transplantation, which deepens the response and prolongs survival. Maintenance therapy with lenalidomide following transplant or induction has become standard, prolonging progression-free and overall survival.

Autologous stem cell transplantation remains a cornerstone of myeloma treatment for eligible patients, typically those under age 70 with adequate organ function. The conditioning regimen uses high-dose melphalan at myeloablative doses to achieve maximal tumor cell kill. The benefit of transplantation lies in deepening the response achieved with induction therapy, converting partial responses to complete responses and pushing more patients toward MRD negativity. Timing of transplantation is typically after 4 to 6 cycles of induction therapy, allowing sufficient disease control before the intensive conditioning. Tandem autologous transplantation, performing two sequential transplants, may be considered for patients with high-risk cytogenetics who do not achieve an adequate response to the first transplant, though this approach must be weighed against the cumulative toxicity of two transplant procedures.

<image>Panel A: Drug class mechanisms showing proteasome inhibitors blocking protein degradation, IMiDs with immunomodulatory and anti-angiogenic effects, and anti-CD38 antibodies targeting plasma cell surface. Panel B: Transplant-eligible pathway from VRd induction through stem cell collection to high-dose melphalan conditioning and autologous transplant. Panel C: Treatment algorithm stratified by transplant eligibility with triplet induction regimens and maintenance lenalidomide. Panel D: Supportive care components including bisphosphonates for bone disease, infection prophylaxis, and VTE prevention with IMiDs.</image>

VI. Relapsed/Refractory Myeloma

The treatment of relapsed or refractory multiple myeloma requires a strategic approach that accounts for prior therapy exposure, duration of initial remission, and the patient's current functional status and comorbidities. The general strategy for second-line therapy involves selecting a combination that includes at least one drug class to which the patient has not been previously exposed, optimizing the chance of response to agents with a different mechanism of action. If a patient achieved a long initial remission, retreatment with the same or similar regimen may be considered, as prolonged remission suggests ongoing sensitivity to those drug classes. Clinical trials remain an important option at every stage of relapsed disease, providing access to novel agents and combination strategies that may improve outcomes beyond what is achievable with currently approved therapies.

Novel agents have dramatically expanded the therapeutic landscape for relapsed and refractory myeloma, with several classes of drugs providing new mechanisms of action for patients who have exhausted standard options. Selinexor is an XPO1 (exportin 1) inhibitor that blocks nuclear export of tumor suppressor proteins, forcing their retention in the nucleus. Venetoclax, a BCL2 inhibitor, has demonstrated particular activity in myeloma harboring the t(11;14) translocation, which is associated with BCL2 dependence. Belantamab mafodotin is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), a surface protein highly expressed on myeloma cells. The BCMA-targeting CAR-T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel have demonstrated remarkable response rates in heavily pretreated patients. Bispecific antibodies including teclistamab and elranatamab redirect T cells to kill BCMA-expressing myeloma cells and represent an off-the-shelf immunotherapy alternative to the manufacturing-intensive CAR-T approach.

Supportive care is an essential component of myeloma management throughout the disease course, addressing the multiple complications that arise from both the disease and its treatment. Bone disease requires treatment with bisphosphonates, most commonly zoledronic acid administered intravenously, or denosumab, a RANKL inhibitor, to reduce skeletal events and prevent further lytic destruction. Infection prophylaxis includes acyclovir to prevent herpes zoster reactivation, particularly with proteasome inhibitor therapy, and trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis during high-dose dexamethasone therapy, along with attention to vaccinations. Anemia management may include erythropoiesis-stimulating agents or transfusions as needed. Renal protective measures involve avoiding nephrotoxins and urgently treating cast nephropathy with rapid disease reduction. Venous thromboembolism prophylaxis with aspirin or therapeutic anticoagulation is mandatory when IMiDs are used, as lenalidomide and pomalidomide significantly increase VTE risk. Appropriate pain management with attention to renal dosing is important for the many patients suffering from bone pain.

Emerging approaches in myeloma therapy continue to push the boundaries of disease control and are reshaping the treatment paradigm. BCMA-targeted therapy has become the dominant theme in novel drug development, with multiple modalities including CAR-T cells, bispecific antibodies, and antibody-drug conjugates all demonstrating clinical activity against this plasma cell-specific target. Maintenance therapy combinations incorporating novel agents beyond lenalidomide alone are being evaluated in ongoing clinical trials. Quadruplet induction regimens adding a fourth drug, typically an anti-CD38 antibody, to standard triplet therapy are becoming the new standard of care as data demonstrate improved depth of response and progression-free survival with four-drug combinations.

<image>Panel A: BCMA as therapeutic target on plasma cell surface with multiple targeting approaches including CAR-T cells, bispecific antibodies, and antibody-drug conjugates. Panel B: CAR-T cell therapy mechanism showing T-cell engineering, expansion, and targeting of BCMA-positive myeloma cells. Panel C: Bispecific antibody structure with one arm binding T-cell CD3 and other binding BCMA to redirect T-cell killing. Panel D: Treatment sequencing algorithm for relapsed myeloma from second-line combination therapy through novel agents to immunotherapy approaches.</image>

VII. MGUS and Smoldering Myeloma

Monoclonal gammopathy of undetermined significance is defined by the presence of a serum M-protein less than 3 g/dL, fewer than 10 percent bone marrow plasma cells, and no evidence of CRAB criteria or myeloma-defining events, representing a pre-malignant condition that is remarkably common in the aging population with a prevalence of approximately 3 percent in adults over age 70. MGUS is the obligate precursor to multiple myeloma, meaning that virtually all cases of myeloma arise from a pre-existing MGUS clone, though the vast majority of MGUS patients will never develop myeloma during their lifetime. The condition is typically discovered incidentally during evaluation for elevated total protein, elevated sedimentation rate, or during workup of unrelated medical conditions. The clinical significance of MGUS lies in its potential for malignant transformation, necessitating long-term monitoring to detect progression at an early stage.

The risk of progression from MGUS to myeloma or a related malignancy averages approximately 1 percent per year, but this risk is not uniform and can be stratified using several readily available clinical and laboratory features. An M-protein level greater than 1.5 g/dL confers higher risk of progression compared to lower M-protein levels. Non-IgG M-protein type, particularly IgA and IgM, carries higher risk than IgG MGUS. An abnormal serum free light chain ratio indicates imbalanced light chain production suggesting a more committed malignant clone and predicts higher progression risk. When all three risk factors are present, the 20-year risk of progression may exceed 50 percent, while patients with no risk factors have a substantially lower cumulative risk. This risk stratification informs the monitoring schedule, with higher-risk patients warranting more frequent surveillance.

Smoldering multiple myeloma occupies the intermediate position between MGUS and active myeloma, defined by a serum M-protein of 3 g/dL or greater or bone marrow plasma cells of 10 percent or greater, but without any CRAB criteria or myeloma-defining events indicating end-organ damage. The rate of progression from smoldering myeloma to active myeloma requiring treatment is substantially higher than MGUS, approximately 10 percent per year for the first 5 years, then declining in subsequent years as the remaining patients represent a biologically more indolent subpopulation. This significant progression risk has prompted investigation of early treatment strategies for high-risk smoldering myeloma patients, with some studies demonstrating benefit from early intervention with lenalidomide-based therapy.

The management of MGUS and smoldering myeloma centers on appropriate monitoring tailored to the estimated risk of progression. Low-risk MGUS patients are monitored annually with serum protein electrophoresis, complete blood count, creatinine, and calcium, with the monitoring interval potentially extended after several years of stability. High-risk MGUS patients are monitored every 6 months with the same panel of tests to detect early signs of progression. Smoldering myeloma patients at low risk for progression are monitored every 3 to 6 months. High-risk smoldering myeloma patients may benefit from early treatment based on accumulating clinical trial data, or at minimum require close monitoring every 3 months with a low threshold for initiating therapy. The identification of high-risk smoldering myeloma patients who may benefit from early therapeutic intervention represents an active area of clinical investigation.

<image>Panel A: Disease progression continuum from MGUS with 1% per year progression risk through smoldering myeloma with 10% per year risk to active myeloma. Panel B: MGUS risk stratification based on M-protein level, non-IgG type, and abnormal free light chain ratio with corresponding monitoring frequency. Panel C: Smoldering myeloma prognostic features identifying high-risk patients who may benefit from early intervention versus low-risk for observation. Panel D: Monitoring schedule showing annual follow-up for low-risk MGUS, every 6 months for high-risk, and every 3-6 months for smoldering myeloma.</image>

VIII. AL Amyloidosis

AL amyloidosis is a systemic disorder caused by the deposition of misfolded immunoglobulin light chains produced by a clonal plasma cell population, with these misfolded proteins polymerizing into insoluble amyloid fibrils that infiltrate and damage multiple organ systems. The light chains in AL amyloidosis adopt an abnormal beta-pleated sheet configuration that renders them resistant to normal proteolytic degradation, allowing progressive tissue accumulation. Lambda light chains are more commonly involved than kappa light chains in AL amyloidosis, the opposite of the kappa predominance seen in light chain deposition disease. The pathognomonic diagnostic stain is Congo red, which binds to amyloid fibrils and produces characteristic apple-green birefringence when viewed under polarized light microscopy, providing definitive tissue confirmation of amyloid deposition. The distinction between AL amyloidosis and other forms of amyloidosis, including AA (serum amyloid A) and hereditary transthyretin amyloidosis, is critical because the treatment approach differs entirely depending on the precursor protein.

The clinical manifestations of AL amyloidosis are protean, reflecting the widespread tissue deposition of amyloid fibrils in virtually any organ system. Cardiac involvement produces a restrictive cardiomyopathy with diastolic dysfunction, low-voltage QRS complexes on electrocardiogram despite thickened ventricular walls on echocardiography, and progressive heart failure that is the primary determinant of prognosis. Renal involvement manifests as nephrotic syndrome with heavy proteinuria from glomerular amyloid deposition. Hepatic involvement causes hepatomegaly with a characteristically elevated alkaline phosphatase disproportionate to other liver enzymes. Gastrointestinal involvement produces macroglossia, a classic and highly suggestive finding in which the tongue becomes enlarged and may show lateral indentations from the teeth, along with malabsorption from intestinal wall infiltration. Peripheral and autonomic neuropathy may cause sensory symptoms, orthostatic hypotension, and gastrointestinal dysmotility. Soft tissue deposition produces the classic findings of periorbital purpura, often called "raccoon eyes," and carpal tunnel syndrome, both of which may precede the diagnosis.

The diagnostic workup for AL amyloidosis involves confirming amyloid deposition, identifying the precursor protein as immunoglobulin light chain, and assessing the extent of organ involvement. Abdominal fat pad aspiration with Congo red staining is the least invasive initial screening test, providing a tissue diagnosis without the need for organ biopsy. Bone marrow biopsy reveals the underlying clonal plasma cell population, which is often modest in size compared to myeloma, and may also demonstrate amyloid deposition within the marrow. When the fat pad aspirate is negative but clinical suspicion remains high, biopsy of the target organ may be necessary for definitive tissue diagnosis. Mass spectrometry performed on amyloid deposits provides the most reliable identification of the amyloid type, distinguishing AL from AA and hereditary forms. Cardiac biomarkers, specifically troponin and NT-proBNP, are used for cardiac staging and prognostication, as the level of cardiac involvement is the primary determinant of survival.

Treatment of AL amyloidosis aims to rapidly eliminate the clonal plasma cell source of the toxic light chains to halt further amyloid deposition and allow potential organ recovery. The current standard first-line regimen is daratumumab combined with bortezomib, cyclophosphamide, and dexamethasone (Dara-VCd), which achieves high rates of hematologic response. Transplant-eligible patients may proceed to autologous stem cell transplantation after induction to deepen the response, though eligibility criteria are more restrictive than in myeloma due to the organ dysfunction common in amyloidosis. The goal of therapy is rapid and deep hematologic response, as the rate of organ improvement correlates with the speed and depth of light chain reduction. Supportive care includes careful diuretic management for heart failure and nephrotic syndrome, with the important caveat that digoxin should be avoided because it binds to amyloid fibrils and can cause fatal toxicity at standard doses. The prognosis of AL amyloidosis depends primarily on the degree of cardiac involvement at diagnosis, with advanced cardiac amyloidosis carrying median survival measured in months despite therapy.

<image>Panel A: Congo red staining demonstrating amyloid deposits with characteristic apple-green birefringence under polarized light microscopy. Panel B: Clinical photograph showing macroglossia with tongue indentations from teeth and periorbital purpura characteristic of AL amyloidosis. Panel C: Cardiac MRI with late gadolinium enhancement showing diffuse subendocardial uptake pattern in cardiac amyloidosis with restrictive physiology. Panel D: Organ involvement distribution showing cardiac, renal, hepatic, and peripheral nerve manifestations with corresponding clinical features.</image>

IX. Waldenström Macroglobulinemia

Waldenstrom macroglobulinemia is a distinct lymphoplasmacytic lymphoma defined by the production of an IgM monoclonal protein and the presence of the MYD88 L265P mutation in more than 90 percent of cases, behaving as an indolent lymphoma with unique clinical features related to the large size and physical properties of the IgM pentamer. The lymphoplasmacytic cells that constitute the malignant clone show features intermediate between mature lymphocytes and plasma cells, reflecting their derivation from B cells at a late stage of differentiation. The MYD88 L265P mutation activates nuclear factor kappa-B and related survival pathways through constitutive signaling, and its near-universal presence in Waldenstrom macroglobulinemia provides an important diagnostic marker distinguishing this entity from other IgM-producing lymphomas. The indolent clinical behavior allows many patients to be observed without treatment for extended periods, similar to the watch-and-wait approach used in other low-grade lymphomas.

The clinical features of Waldenstrom macroglobulinemia reflect both the consequences of the lymphoplasmacytic infiltrate in marrow and lymphoid tissues and the unique properties of the IgM M-protein. Hyperviscosity syndrome is the most characteristic clinical manifestation, caused by the tendency of IgM, a large pentameric molecule, to aggregate and increase serum viscosity. Cryoglobulinemia, in which the IgM precipitates at cold temperatures, can cause Raynaud phenomenon, purpura, and peripheral neuropathy. Anemia results from bone marrow infiltration by the lymphoplasmacytic cells and is a common indication for treatment initiation. Lymphadenopathy from nodal involvement is present in a subset of patients. Peripheral neuropathy may be caused by antibodies directed against myelin-associated glycoprotein (anti-MAG antibodies), representing an autoimmune complication of the monoclonal IgM. An important clinical distinction from multiple myeloma is the absence of lytic bone lesions in Waldenstrom macroglobulinemia.

Hyperviscosity syndrome deserves particular emphasis as a medical emergency that occurs when the serum viscosity exceeds 4 centipoise and produces a characteristic clinical triad affecting vision, the nervous system, and mucosal surfaces. Visual symptoms include blurred vision and diplopia from retinal vein engorgement and hemorrhages. Neurologic manifestations include headache, confusion, and stroke-like symptoms from impaired cerebral microcirculation. Mucosal bleeding from the nose and gums reflects the coagulopathy associated with hyperviscosity. Fundoscopic examination reveals the classic finding of "sausage-link" retinal veins, characterized by alternating dilation and constriction of the venous vessels, along with retinal hemorrhages and sometimes papilledema. The emergency treatment of hyperviscosity syndrome is plasmapheresis, which rapidly removes the large IgM molecules from the circulation and provides immediate symptomatic relief while definitive disease-directed therapy is initiated.

The treatment of Waldenstrom macroglobulinemia is reserved for symptomatic patients, with asymptomatic individuals followed by observation alone given the indolent natural history. When treatment is indicated, rituximab-based combination regimens are the standard approach, with bendamustine-rituximab (BR) and dexamethasone-rituximab-cyclophosphamide (DRC) among the commonly used protocols. BTK inhibitors including ibrutinib and zanubrutinib have demonstrated high efficacy in Waldenstrom macroglobulinemia and are increasingly used as frontline therapy, leveraging the dependence of the malignant clone on B-cell receptor signaling through the MYD88-mediated pathway. An important clinical consideration is that rituximab should not be used alone as initial therapy because it can trigger a transient increase in IgM levels known as an IgM flare, potentially precipitating or worsening hyperviscosity symptoms. For patients presenting with symptomatic hyperviscosity, urgent plasmapheresis should be performed before initiating definitive therapy to achieve rapid reduction in serum viscosity and relieve symptoms.

<image>Panel A: IgM pentamer structure explaining propensity for hyperviscosity due to large molecular size and aggregation. Panel B: Fundoscopic examination showing sausage-link venous engorgement, retinal hemorrhages, and papilledema in hyperviscosity syndrome. Panel C: MYD88 L265P mutation present in over 90% of Waldenstrom cases with role in B-cell receptor signaling. Panel D: Treatment algorithm from observation for asymptomatic disease through rituximab-based therapy to BTK inhibitors with urgent plasmapheresis for hyperviscosity.</image>

X. Other Plasma Cell Disorders

Plasma cell leukemia is the most aggressive manifestation of plasma cell neoplasia, defined by the presence of 2 billion or more plasma cells per liter of peripheral blood or plasma cells constituting more than 20 percent of the peripheral blood white cell differential. Primary plasma cell leukemia arises de novo without a preceding history of myeloma, while secondary plasma cell leukemia represents the leukemic transformation of pre-existing multiple myeloma during disease progression. The prognosis of plasma cell leukemia is very poor, with rapid progression and resistance to many standard myeloma therapies. Treatment requires intensive combination therapy with consideration of autologous or allogeneic stem cell transplantation in eligible patients, though outcomes remain substantially worse than for standard multiple myeloma despite aggressive intervention.

Solitary plasmacytoma represents a localized plasma cell neoplasm occurring as a single tumor without evidence of systemic disease, and is classified by its anatomic location as either solitary bone plasmacytoma or extramedullary plasmacytoma. Solitary bone plasmacytoma presents as a single lytic lesion, while extramedullary plasmacytoma arises in soft tissues with the head and neck region being the most common site. The diagnostic workup must confirm the absence of systemic myeloma through bone marrow biopsy, whole-body imaging, and M-protein quantification. Treatment is radiation therapy, which achieves high local control rates. Long-term follow-up is essential because a significant proportion of patients, particularly those with solitary bone plasmacytoma, will eventually develop multiple myeloma, requiring ongoing monitoring with serum protein electrophoresis and imaging.

POEMS syndrome is a rare paraneoplastic disorder associated with an underlying plasma cell neoplasm that produces a characteristic constellation of findings captured by the acronym: Polyneuropathy, Organomegaly, Endocrinopathy, M-protein (characteristically lambda light chain), and Skin changes. Additional features not captured in the acronym include sclerotic rather than lytic bone lesions, which is the opposite of typical myeloma, and elevated vascular endothelial growth factor (VEGF) levels that serve as both a diagnostic marker and a mediator of disease manifestations. The M-protein is characteristically lambda light chain restricted, distinguishing it from the kappa predominance seen in light chain deposition disease. Treatment depends on the extent of disease: patients with limited skeletal disease may be treated with radiation alone, while those with diffuse disease require systemic therapy with autologous stem cell transplantation in eligible patients.

Light chain deposition disease is a systemic disorder caused by deposition of monoclonal light chains in tissues in a non-amyloid pattern, distinguishing it from AL amyloidosis despite sharing a common etiology in clonal plasma cell-produced light chains. The deposits consist of non-fibrillar light chains that do not adopt the beta-pleated sheet configuration characteristic of amyloid and therefore do not stain with Congo red, an important distinction from AL amyloidosis. The kidney is the most commonly affected organ, where light chain deposition produces nodular glomerulosclerosis with thickening of tubular and glomerular basement membranes. In contrast to AL amyloidosis where lambda light chains predominate, light chain deposition disease demonstrates kappa light chain predominance. Treatment follows myeloma-directed therapy to eliminate the clonal plasma cell source of the pathologic light chains.

<image>Panel A: Plasma cell leukemia peripheral smear showing circulating plasma cells exceeding 2 billion per liter with aggressive clinical course. Panel B: POEMS syndrome features with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes plus sclerotic bone lesions and elevated VEGF. Panel C: Solitary plasmacytoma on imaging with single lytic bone lesion or extramedullary soft tissue mass requiring radiation therapy. Panel D: Light chain deposition disease comparison with AL amyloidosis showing nodular glomerulosclerosis, kappa predominance, and Congo red negativity.</image>

Summary

• Plasma cell disorders: Spectrum from MGUS to myeloma to amyloidosis
• Multiple myeloma: CRAB criteria + clonal plasma cells; lytic bone disease
• R-ISS staging: β2-microglobulin, albumin, LDH, cytogenetics
• Myeloma treatment: Triplet therapy (VRd); transplant if eligible; maintenance lenalidomide
• MGUS: <3 g/dL M-protein, <10% plasma cells; 1%/year progression risk
• Smoldering myeloma: Higher M-protein/plasma cells; no CRAB; ~10%/year progression
• AL amyloidosis: Light chain deposits; Congo red positive; cardiac involvement determines prognosis
• Waldenström: IgM M-protein; hyperviscosity; MYD88 mutation; indolent
• Supportive care: Bisphosphonates, infection prophylaxis, VTE prophylaxis

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown